双特异性抗体 (ABL602 2 + 1) 诱导的可比化的急性髓性白血病动力学
Shilian Xu1,2
1Department of Environment and Genetics, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, Australia. Shilian.Xu@latrobe.edu.au.
Scientific reports
|October 27, 2024
概括
针对白血病细胞和T细胞的双特异性抗体表现出复杂的行为. 它们的有效性取决于瘤负担,高负担会降低有效性,突出显示需要持续的抗体水平和T细胞功能.
科学领域:
- 免疫学 免疫学 免疫学
- 数学生物学 数学生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 双特异性抗体,如ABL602 2+1,针对白血病细胞 (通过CLL-1) 和T细胞 (通过CD3) 增强抗癌活性.
- 双特异性抗体治疗,癌细胞复制和瘤溶解动态之间的关系没有得到定量理解.
研究的目的:
- 通过使用数学建模在双特异性抗体治疗下对HL-60细胞的动力学进行定量研究.
- 阐明双特异抗体度,T细胞度和瘤负担之间的复杂相互作用.
主要方法:
- 对涉及HL-60细胞,T细胞和ABL602 2+1双特异抗体的细胞毒性测定数据的分析.
- 开发和应用数学模型来模拟细胞动力学和治疗结果.
主要成果:
- 双特异性抗体的瘤溶解效率随着目标细胞,T细胞和抗体度的增加而和.
- 一个双稳定动力模型解释了HL-60细胞动力学如何在低瘤负担时被抑制,但在高瘤负担时变得耐火.
- T细胞度与HL-60细胞度相反相关,即使在抗体清除后,这种双相稳定性仍然存在.
结论:
- 在高瘤负担下,双特异性抗体的有效性降低,即使有足够的T细胞,由于复杂的动力相互作用.
- 维持高双特异性抗体度和防止T细胞枯竭对于实现长期疾病控制至关重要.
关键词:
ABL602 2 + 1 2 + 1 ABL602 2 + 1 ABL602 2 + 1 ABL602 2 + 1 ABL602 2 + 1 ABL602 ABL602 2 + 1 ABL602 2 + 1 ABL602 ABL602 2 + 1 ABL602 2 + 1 ABL602 ABL602 2 + 1 ABL602 ABL602 ABL602 2 + 1 ABL602 ABL602 2 + 1 ABL602 ABL602 2 + 1 ABL602 ABL602 ABL602 2 + 1 ABL602 ABL602 ABL602 2 + 1 ABL602 ABL602 2 + 1 ABL602 ABL602 ABL602急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.双特异性抗体 双特异性抗体两性可靠性 两性可靠性免疫治疗是一种免疫疗法.增加了瘤负担.更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K